Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data. That data arrived Tuesday night. And while it is stoking enthusiasm that physicians might soon be able […]
That Blockbuster Alzheimer’s Drug? It’s Not a Cure (Links to an external site)








